Abstract Body

Background

To evaluate the efficacy and safety of double-dose dolutegravir plus lamivudine (2DR) versus an efavirenz-based three-drug regimen (3DR) in antiretroviral-naïve adults coinfected with HIV and tuberculosis (TB) who had initiated rifampicin-based anti-TB therapy within the previous two weeks. 

Methods

In this multicenter, open-label, randomized trial (ChiCTR2300075493), participants were assigned (1:1) to receive either dolutegravir (50 mg twice daily) plus lamivudine (2DR), or efavirenz (600 mg daily) with tenofovir and lamivudine (3DR). Antiretroviral therapy (ART) was started two weeks after anti-TB treatment initiation. The primary outcome was virological suppression (HIV-1 RNA <50 copies/mL) at week 24, analyzed in both the modified intention-to-treat (mITT) population (participants who received at least one dose of study medication) and the per-protocol set (PPS).

Results

A total of 127 participants were included in the mITT analysis (2DR: n=69; 3DR: n=58); 90 completed week 24 (2DR: 49; 3DR: 41), with 58 in the PPS (2DR: 38; 3DR: 20). Baseline characteristics were similar, though the 2DR group had higher baseline viral load (mean 5.6 vs. 5.2 log10 copies/mL) and more with HIV RNA ≥500,000 copies/mL (46.9% vs. 26.8%). Median CD4⁺counts were 47 cells/μL (2DR) and 44 cells/μL (3DR). In the mITT, virological suppression at week 24 was 63.3% (31/49) in the 2DR group versus 51.2% (21/41) in the 3DR group (P = 0.249). In the PPS, rates were 76.3% (29/38) and 95.0% (19/20), respectively (P = 0.154). Among those with high baseline viral load (≥500,000 copies/mL), mITT suppression was 56.5% (2DR) vs. 45.5% (3DR) (P = 0.717); in PPS, 75.0% vs. 100% (P = 0.532). Three virologic failures occurred in the 3DR group, all with high-level efavirenz resistance. Two 2DR participants had detectable virus at week 24 but achieved suppression by week 48. Twelve immune reconstitution inflammatory syndrome (IRIS) events occurred (9 in 2DR, 3 in 3DR), none leading to discontinuation. Common adverse events included rifampin-related toxicity (n=6) and efavirenz-related hypersensitivity (n=5).

Conclusions

Double-dose dolutegravir plus lamivudine showed comparable efficacy to a standard efavirenz-based regimen in HIV/TB-coinfected patients on rifampicin, suggesting it may be a viable dual-therapy option for this population.